In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Chemours Company (NYSE: CC) closed at $11.69 down -0.76% from its previous closing price of $11.78. In other words, the price has decreased by -$0.76 from its previous closing price. On the day, 2.03 million shares were traded. CC stock price reached its highest trading level at $11.95 during the session, while it also had its lowest trading level at $11.55.
Ratios:
For a deeper understanding of Chemours Company’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.88 and its Current Ratio is at 1.71. In the meantime, Its Debt-to-Equity ratio is 14.82 whereas as Long-Term Debt/Eq ratio is at 14.43.
On January 28, 2025, Truist started tracking the stock assigning a Buy rating and target price of $27.
UBS Upgraded its Neutral to Buy on July 09, 2024, whereas the target price for the stock was revised from $28 to $30.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 08 ’25 when Dignam Denise bought 4,068 shares for $12.06 per share. The transaction valued at 49,060 led to the insider holds 191,546 shares of the business.
Gumpel Damian bought 13,400 shares of CC for $123,548 on Jun 02 ’25. The insider now owns 123,879 shares after completing the transaction at $9.22 per share. On Jun 03 ’25, another insider, Gumpel Damian, who serves as the insider of the company, bought 7,822 shares for $9.95 each. As a result, the insider paid 77,828 and bolstered with 131,701 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CC now has a Market Capitalization of 1752236800 and an Enterprise Value of 5560237056. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.26. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.30 while its Price-to-Book (P/B) ratio in mrq is 5.88. Its current Enterprise Value per Revenue stands at 0.953 whereas that against EBITDA is 8.437.
Stock Price History:
The Beta on a monthly basis for CC is 1.60, which has changed by -0.3214286 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, CC has reached a high of $20.12, while it has fallen to a 52-week low of $9.13. The 50-Day Moving Average of the stock is -8.50%, while the 200-Day Moving Average is calculated to be -10.47%.
Shares Statistics:
For the past three months, CC has traded an average of 2.88M shares per day and 2274820 over the past ten days. A total of 149.87M shares are outstanding, with a floating share count of 148.79M. Insiders hold about 0.73% of the company’s shares, while institutions hold 94.86% stake in the company. Shares short for CC as of 1764288000 were 13505133 with a Short Ratio of 4.68, compared to 1761868800 on 13127071. Therefore, it implies a Short% of Shares Outstanding of 13505133 and a Short% of Float of 13.239999.
Dividends & Splits
According to the company, the forward annual dividend rate for CC is 0.51, from 0.675 in the trailing year. Against a Trailing Annual Dividend Yield of 0.05730051. The stock’s 5-year Average Dividend Yield is 4.06.
Earnings Estimates
The firm’s stock currently is rated by 8.0 analysts. The consensus estimate for the next quarter is $0.19, with high estimates of $0.32 and low estimates of $0.1.
Analysts are recommending an EPS of between $1.4 and $0.79 for the fiscal current year, implying an average EPS of $0.97. EPS for the following year is $1.77, with 9.0 analysts recommending between $2.15 and $1.38.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $1.33B this quarter.It ranges from a high estimate of $1.4B to a low estimate of $1.29B. As of. The current estimate, Chemours Company’s year-ago sales were $1.36BFor the next quarter, 7 analysts are estimating revenue of $1.44B. There is a high estimate of $1.46B for the next quarter, whereas the lowest estimate is $1.42B.
A total of 9 analysts have provided revenue estimates for CC’s current fiscal year. The highest revenue estimate was $5.87B, while the lowest revenue estimate was $5.77B, resulting in an average revenue estimate of $5.8B. In the same quarter a year ago, actual revenue was $5.78BBased on 9 analysts’ estimates, the company’s revenue will be $6.04B in the next fiscal year. The high estimate is $6.17B and the low estimate is $5.96B.
